The Oxidative and Cytotoxic Effects of Resveratrol Compared With Cisplatin in the LNCap Prostate Cancer Cell Line

Prostate cancer is one of the most common diseases worldwide, and many efforts are made to treat this disease; however, these efforts seem to be futile. Accordingly, this study tends to compare the cytotoxic and oxidative (as shown by the production of reactive oxygen species (ROS)) effects of resveratrol in comparison with cisplatin in a prostate cancer cell line (LNCap).

After treatment of LNCap cells with the concentrations of 1, 10, 100, 500, and 1000 µg/mL of resveratrol, and 1, 5, 10, and 50 µg/mL of cisplatin, the viability percentage of cells was analyzed using MTT and spectrophotometry. Also, ROS production in this cell line at the IC50 concentrations of cisplatin and resveratrol was analyzed using flow cytometry.

The results of the MTT test showed that cisplatin and resveratrol could both reduce cell viability at high concentrations because of increased cytotoxicity. Measurement of ROS production showed that cisplatin and resveratrol increased ROS levels compared to control cells.

The results obtained from this study showed that resveratrol, as a plant derivative, had anticancer and antioxidant properties against the LNCap prostate cancer cell line. Because of the side effects of cisplatin, it can be replaced by resveratrol as a good candidate to be used in chemotherapy.